ArticleInternal medicine (Tokyo, Japan)2026
Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Managing capivasertib-induced hyperglycemia: a report of 3 cases.JCEM case reports · 2026Article
- Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein report a case of hyperglycemia in a patient with recurrent breast cancer treated with the AKT inhibitor capivasertib. Continuous glucose monitoring revealed a distinctive pattern characterized by pronounced daytime postprandial hyperglycemia and nocturnal-to-morning decline, which resolved during the drug-free intervals. Hyperglycemia was unresponsive to metformin treatment but was markedly exacerbated by intravenous glucose infusion. These findings suggest that capivasertib-induced hyperglycemia is caused by an impaired glucose uptake and dysregulated hepatic glucose output associated with AKT inhibition. Careful glycemic monitoring and individualized management are necessary in patients receiving AKT inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.